Alvotech

NASDAQ:ALVO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.55 -1.02%

-$0.04 today

Market cap
$1.62B
Beta
0.21
P/E (TTM)
-15.9
EPS (TTM)
-$0.24
52W Low $2.94High $9.94

Volume 1.56M

Average 0.65M

ALVO EBITDA Margin

EBITDA as a percentage of revenue.

AlvotechNASDAQ: ALVO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 49.2%

EBITDA Margin was 49.2% in Q1 FY2026, down 54.2 pp from a year earlier. On a trailing-twelve-month basis it was 9.3%, down 14.4 pp year over year. Over 3 fiscal years it widened by 584.9 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 33.8% for the fiscal year ending Dec 2026, down from 55.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
49.2%+100.0 pp QoQ
Last fiscal yearDec 2025
55.2%+61.7 pp YoY
LTMMar 2026
9.3%-14.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-54.2 pp+3.2 pp+57.4 pp
1 year+61.7 pp-21.4 pp-83.1 pp
3 years+584.9 pp+1.1 pp-583.7 pp
5 years+17.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
55.2%
Year-over-year change
+61.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ALVO compares with its peers on the latest reported figures

  • ALVO's LTM Mar 2026 EBITDA Margin of 9.3% is the 10th highest of the 11 companies compared; the peer median is 21.1%.
  • Its year-over-year change of -14.4 pp is the lowest of 11, against a peer median of -0.3 pp.
  • Over three fiscal years its change of +584.9 pp compares with a peer median of +0.2 pp.
ALVO Competitors Peer median
EBITDA Margin for ALVO and competitors
Company Period LTM level YoY 3-year change
COLLCollegium Pharmaceutical, Inc.LTM Mar 202676.6% +26.5 pp+14.0 pp
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202637.0% -1.1 pp-2.6 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202626.6% -9.0 pp+0.2 pp
OGNOrganon & Co.LTM Sep 202621.2% -3.6 pp-7.7 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202620.9% +0.5 pp+0.1 pp
BIIBBiogen Inc.LTM Jun 202619.7% -14.2 pp-4.7 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202615.0% -2.9 pp+24.4 pp
HROWHarrow Health, Inc.LTM Mar 202611.7% +3.4 pp+19.6 pp
ALVOAlvotechLTM Mar 20269.3% -14.4 pp+584.9 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 20266.3% +9.1 pp+39.4 pp
Peer median (excluding ALVO) 21.1%-0.3 pp+0.2 pp

Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.77M83.03M91.43M489.68M586.32M
Cost of Revenue064.1M160.86M185.31M235.56M
Gross Profit36.77M18.93M(69.42M)304.37M350.76M
Gross Margin100.0%22.8%-75.9%62.2%59.8%
Research & Development191.01M180.62M210.83M171.31M184.19M
Selling, General & Admin84.13M186.74M73.04M61.45M90.95M
Operating Expenses272.23M365.38M285.44M234.73M272.56M
Depreciation & Amortization18.2M20.41M24.21M31.3M37.85M
EBITDA(18.03M)(439.8M)(493.67M)(32.28M)323.39M
EBITDA Margin-49.0%-529.7%-539.9%-6.6%55.2%
Operating Income(235.46M)(346.44M)(354.86M)69.64M78.21M
Operating Margin-640.3%-417.3%-388.1%14.2%13.3%
Interest Income19K912K4.82M4.62M198.49M
Interest Expense112.97M91.44M134.82M157.6M149.19M
Other Income / Expenses86.26M(205.21M)(296.19M)(287.21M)58.14M
Income Before Tax(149.2M)(551.65M)(651.05M)(217.56M)136.35M
Pre-Tax Margin-405.7%-664.4%-712.0%-44.4%23.3%
Income Tax Expense(47.69M)(38.07M)(99.32M)14.3M108.43M
Net Income(101.5M)(513.58M)(551.73M)(231.86M)27.92M
Net Margin-276.0%-618.6%-603.4%-47.3%4.8%
EPS (Basic)(3.25)(2.60)(2.43)(0.87)0.10
EPS (Diluted)(3.25)(2.60)(2.43)(0.87)0.10
Weighted Avg Shares31.25M197.72M227.26M267.92M279.19M
Weighted Avg Shares (Diluted)31.25M197.72M227.26M267.92M279.19M

Alvotech

NASDAQ:ALVO

Intrinsic Alpha fair value

Locked

Current Price

$4.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.